

Cumulative Index 2005

Note: Page numbers of article titles are in **boldface** type.

A

- Abstinence syndrome, in benzodiazepines withdrawal, 213
- Actigraphy, in sedation assessment, 207
in sedation evaluation, 292–293
- Acute care nurse practice, strategies for, **169–175**
- Acute care nurse practitioner (ACNP) role, **171–181**
collaborative relationships and, 179
communication about, 177–178
communication within, 178
competency in, maintenance of, 178–179
demonstrating practice outcomes in, 180
recommendations for, 179
- Acute lung injury (ALI), **311–318**
assessment of, 316
chemical relaxants for, 316
clinical indications of, 312
corticosteroids for, 313–314
definition of, 311
diagnostic criteria for, 311
high-frequency oscillatory ventilation for, 313
lung protective strategies for, 312–313
mechanical ventilation for, 312–313
nursing care in, 315–317
nutrition in, 315
pathophysiology of, 311–312
prone positioning for, nurse's role in, 316–317
responders *versus* nonresponders, 314
timing of, 314
pulmonary hygiene for, 316
rescue therapy for, 315
sedation for, 316
vasodilatory therapy, inhaled, 313
- Acute respiratory distress syndrome (ARDS), **311–318**
assessment of, 316
clinical indications of, 312
- corticosteroids for, 313–314
definition of, 311
diagnostic criteria for, 311
high-frequency oscillatory ventilation for, 313
lung protective strategies for, 312–313
mechanical ventilation for, 312
nursing care in, 315–317
nutrition in, 315
pathophysiology of, 311–312
prone positioning for, nurse's role in, 316–317
timing of, 314
pulmonary hygiene for, 316
relaxants for, chemical, 316
rescue therapy for, 315
sedation for, 316
vasodilator therapy for, inhaled, 313
- Adaptation to the intensive care environment (ATICE) scale, in sedation assessment, 291, 293
- Adrenoceptors, physiologic response to vasopressors, 71–72
organ location of, 72
- Advanced cardiac life support (ACLS),
pharmacology for, 53–55
teaching of, simulation in, 5
- Advance directives, nurses' emerging role in, 198
- Advanced life support transportation, 207
- Adverse responses, to sedation, analgesia, and neuromuscular blocking agents, **441–450**
corneal abrasion, 447
cost associated with, 447–448
gastrointestinal, 446–447
muscular, 444–445
tolerance, dependence, and withdrawal, 441–443
- Airway management, for health care providers, International Guidelines 2000 Conference recommendations, 52–54
in patient transport, 205–206

- Alcohol, abuse of, 297
dependence on, 297
obstructive sleep apnea and, 273
systemic effects of, 297-298
- Alcohol withdrawal syndrome, alcoholic hallucinosis in, 298
assessment of, with Clinical Institute Withdrawal Assessment for Alcohol-Revised, 297-304
delirium tremens in, 299
medications for, 301-302
patient assessment in, 299-300
psychologic treatments for, 299, 301
symptoms of, 298
symptom-triggered therapy for, 301-302
- Amiodarone, for atrioventricular re-entry tachycardia, in neonates and infants, 79, 82-83
- Analgesia, adverse responses to, 441-450
post-cardiac surgery, 413-414
- Analgesics, pharmacokinetics of, in critically ill patient, 212
in hepatic dysfunction, 245-248
in renal dysfunction, 248-249
- Anesthesia, and obstructive sleep apnea, 274-275
- Anesthetics, inhalation, for status asthmaticus, 476
- Anthropometry, in nutritional assessment, 386-387
- Anticholinergics, for status asthmaticus, 471-472
- Antidepressants, sedating, for sleep disorders, 231
- Antileukotriene agents, for status asthmaticus, 476
- Antipsychotic drugs, safety issues with, 68
- Apnea. See *Obstructive sleep apnea; Sleep apnea.*
- Arrhythmias, in hypothermia, 101
post-cardiac surgery, 410-411
- Atrial flutter, in children, 80, 83-84
- Atrioventricular block, in children, 81, 92-93
- Atrioventricular re-entry tachycardia (AVRT),
amiodarone for, 79, 82-83
in children, clinical interventions in, 79, 82-83
ECG characteristics of, 79
procainamide for, 83
- B**
- Barbiturates, for sedation, 260
for sleep, pharmacology of, 273
- Bar code technology, in collaboration, 170
- Beacon Award, achievement of, 153-154
establishment of, 149, 164
Georgetown University Hospital, 155-161
application for, 160
challenges and, 160
data collection for, 156
decision to apply for, 155-156
evidence-based practice and research in, 157-158
healing environment in, 157
leadership ethics and, 156
maintenance of, 160-161
organizational ethics and, 156-157
patient outcomes, 158-159
reception of, 160
recruitment and retention, 159-160
steps toward, 156-159
University of California at Davis, 164
- Beacon unit, culture and mission in, 151-152
- Benzodiazepine (BZD) withdrawal syndrome, 212-217, 273
abstinence syndrome in, 213
chart review of, in adult burn patients, 216
in mechanically ventilated adult patients, 216-217
in pediatric patients, 213-215
prospectively repeated measures study, 216
retrospective chart reviews of, 213, 216
- Benzodiazepines (BZDs), in alcohol withdrawal syndrome, 301
for sedation, 260
for sleep, commonly used, 272
pharmacology of, 271-272
for sleep disorders, in cancer patients, 230
- Beta-adrenergic agonists, for status asthmaticus, 470-471
- Beta-blockers, in alcohol withdrawal syndrome, 302
- Bispectral (BIS) monitoring, limitations of, 263
in neurologic examination, 263-264
of sedation, 207, 263, 292
in sedation assessment, 263
and sedation interruption, 257-267
sleep states and, 242-243
- Body temperature, cranial vs. core, 99
lowering of, conduction and convection loss in, 100-101
intravascular techniques, 100-101
medications for, 100
measurement of, body sites in, 99-100

Bradyarrhythmias, in children, atrioventricular block,
81, 92-93
sinus node dysfunction, 81, 91-92

Bronchoscopy, for status asthmaticus, 476

C

CAGE questionnaire, in assessment of alcohol
withdrawal syndrome, 299

Calcium imbalances, overview and case examples,
365, 371-372

Capacity, in evidence-based practice, 127-132
for organizational excellence, 127-132

Cardiac arrest, from cardiac arrhythmias, 71
in children, emotional outcome of, 19-20
long-term survival of, 17
near-death experience of, 19-20
neurologic impairment and, 17, 20
death of children, grief care for family and,
20-21
bereavement committee for, 21
grief conference in, 20-21
hypothermia for neuroprotection following,
98-99
survival of, 71
vasopressors in treatment of, **71-75**
adrenoceptors and, 71-73
dobutamine, 73
dopamine, 73
epinephrine, 73-74
norepinephrine, 73
vasopressin, 74

Cardiac arrhythmias, in children, bradyarrhythmias,
81, 91-93
hemodynamic compromise and, **77-95**
parental education in, 83
pulseless rhythms, 81, 93-94
tachyarrhythmias, 78-91

Cardiac function, description of, 375

Cardiac output. See also *Low cardiac output
syndrome (LCOS)*.
afterload in, 376
contractility and, 376
definition of, 375
heart rate and, 375-376
and oxygen delivery, 376-377
preload in, 376

Cardiac pacing, for intra-atrial re-entrant tachycardia,
in children, 86

Cardiac resuscitation, thermoregulation in, **97-102**.
See also *Thermoregulation, in
cardiac resuscitation*.

Cardiac surgery patient, postoperative management
of, **405-416**
afterload in, 408
analgesia and sedation in, 413-414
arrhythmias in, 410-411
cardiac output in, 408
fluid and electrolytes in, 412
heart rate and contractility in, 408-409
hemodynamic monitoring in, 405-406
infection and, 414
left atrial pressure in, 407
low cardiac output in, 409-410
neurologic, 413
nutritional, 414
preload in, 408
pulmonary hypertension in, 411-412
pulmonary artery pressure in, 407-408
renal, 413
respiratory, 411
right atrial pressure in, 406-407
thermoregulation in, 411

Cardiopulmonary resuscitation (CPR), family
presence during, **23-32**
Methodist Hospital, 152
International Guidelines 2000 Conference and,
51-58
pediatric. See also *Cardiac arrest, in children*.
age and, 59
emotional outcome of, 19-20
outcome of, 17-18
post-resuscitation care, immediate, 18-19

Cardiovascular system, alcohol effect on, 298

Cardioversion, for atrioventricular re-entrant
tachycardia, in children, 79, 82

Central nervous system, alcohol effect on, 298

Children, cardiac arrhythmias in, bradyarrhythmias,
91-93
hemodynamic compromise and, **77-95**
parental education in, 83
pulseless rhythms, 81, 93-94
tachyarrhythmias, 78-91, 79-91
cardiovascular resuscitation in, 17-20
crash cart medication safety and, 67
in Tsunami disaster. See *Tsunami, children in*.

Clarian Professional Practice model, 109
career levels in, 116

- Clarian Safe Passage Program, **121–126**. See also *Medication safety; Safety*.
 characteristics of high reliability organizations in, 121–122
 curriculum in, cognitive task analysis in, 122
 proactive patient safety in, 122–123
 work complexity in, 122–123
 knowledge management and mentoring structure in, 123–124
 Leapfrog Group in, 125
 mentoring in, among safe passage members, 124
 common themes in, 125
 external, 124
 internal, 124
 outcome measures and, 125
 as patient safety check and balance, 125
 patient safety methodology in, 121–122
- Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scale, in assessment of alcohol withdrawal syndrome, 299–300
- Clinical ladder, Nursing Clinical Career Progression Model, at Methodist Hospital, 153
- Clonidine, in alcohol withdrawal syndrome, 302
- Clopidogrel, for acute coronary syndrome, 55
- Code of Ethics for Nurses, and empowered caring, in synergy model, 118
- Collaboration, in acute care practice, acute care nurse practitioner role in, 179
 in adult ICU, committees for, 169–170
 examples of issues and resolution, 170–171
- COMFORT Scale, 291, 293
- Communication, breakdown in, and interdisciplinary collaboration, 144–145
 with house staff on adult ICU, 170
 in peer review process, 117
 for safety in pediatric ICU, among care givers, 433
 daily goals worksheet for, 433–434
 with parents and patients, 433
 situation, background, assessment, and recommendation in, 434
 in transport of critically ill, 187
 at unit level, in evidence-based practice, 135
- Congenital heart disease, parental experience of, **319–327**
 baby's experience of, 324
 as a dream, 322
 as emotional roller coaster, 325
 information in, too little and too much, 523–524
 last kiss after visit, 323
 loss of control, 324
 maternal intuition, 322
 memory of, 325–326
 perception of baby's status, 324–325
 senseless of ICU environment, 323
 shock, disbelief, shattered, 322–323
 studies of, current, 320–326
 historical, 319–320
 time stopped, 323
 trust in, 324
 unconditional love and, 321–322
- Continuing education, for excellence, at Bay State Medical Center, 173
 Georgetown University Hospital, 159
- Core groups, at unit level, in evidence-based practice, 136
- Corneal abrasions, from sedation, analgesia, neuromuscular blocking agents, 447
- Coronary angioplasty, for acute coronary syndrome, 55
- Corticosteroids, for acute lung injury, 313–314
 for acute respiratory distress syndrome, 313–314
 for status asthmaticus, 471–472
- CPR (Cardiopulmonary resuscitation). See *Cardiopulmonary resuscitation (CPR); Resuscitation events*.
- Crash carts, medication safety on, 67
- Critical care transportation, 207
- Critical illness myopathy (CIM), 444
- Critical illness polyneuropathy (CIP), 444
- Cross-tolerance, 211, 212
 of dexmedetomidine and benzodiazepines, 220
- Cultural diversity, patient care and, in synergy model, 118
- Culture, in evidence-based practice, 132–133
 for organizational excellence, 132–133
- Culture of learning, for excellence in adult ICU, 172–173

D

- Death, in pediatric ICU. See also *End-of-life care*.
 caring for children and families, **349–360**
 categories of, 349
 modes of, 349–352

- presence of family members at, 353-354
 - sudden, parents and, 356
 - siblings and, 459-460
 - in trauma center, 356
 - bereavement programs and, 356-357
 - Defibrillation, for cardiac arrest, 52
 - Defibrillator(s), automatic external, 52
 - biphasic, 52
 - Dehydration, types of, 363
 - Delirium, in cancer patient, sleep disturbances and, 229-230
 - Dependence, definition of, 441
 - Dexmedetomidine (DEX), in facilitation of opioid and benzodiazepines withdrawal, 220
 - for sedation, 261
 - of intubated and mechanically ventilated ICU patients, 219
 - Diabetic ketoacidosis (DKA), anion gap in, 344-345
 - complications of, 345
 - counterregulatory hormone activity in, 344
 - diagnosis of, 344
 - hyperglycemia in, 343-344
 - insulin and glucose conduct and, 341
 - lipolysis and, increased, 342-343
 - nursing care in, 346
 - pathophysiology of, 342
 - in pediatric ICU, **341-347**
 - treatment of, 345-346
 - fluid and electrolytes in, 345-346
 - insulin in, 345-346
 - Disulfiram, in alcohol withdrawal syndrome, 302
 - Disuse atrophy, 444
 - Dobutamine, for cardiac arrest, 73
 - for low cardiac output syndrome, 381
 - Dopamine, for cardiac arrest, 73
 - for low cardiac output syndrome, 381
 - Dying process, presence of family members in, 353-354
 - withdrawal of life support in, 353
- E**
-
- Eindhoven classification model, for a medical domain, 283
 - Eindhoven classification system, categories of, 279-280
 - human, 281-284
 - organizational, 280-282
 - technical, 279-280
 - as framework for safety within systems, 279-280
 - Electrolyte imbalances, 364-372
 - calcium, 365, 371-372
 - potassium, 364-365, 369-371
 - sodium, 364, 367-369
 - Emergency cardiac care, International Guidelines 2000 Conference recommendations for, **51-58**
 - Emergency department, medication safety issues in, **65-69**
 - End-of-life care. See also *Death, in pediatric ICU*.
 - decision-making in, clinicians' perspectives, 352-353
 - parental initiation of, 352
 - improvements in, 357-358
 - in pediatric ICU, clinician's attitudes, 354-355
 - decision-making in, parental, 355-356
 - nurses' role in, 354
 - parental perceptions of, 355-356
 - public policy and, nurses' emerging role in, 197-198
 - Endotracheal suctioning
 - complications of, 330
 - cues in clinical judgments about, **329-340**, 330-331
 - recognition of, 331-334
 - recommendations regarding, 337
 - study of, 330-331, 335-337
 - weighing the evidence in, 334-335
 - performance of, skilled, 335
 - Enteral support, **385-393**. See also *Nutritional assessment; Nutritional status*.
 - formulas for, 389-390
 - indications for, 388-389
 - mode in, 391-392
 - nutritional assessment for, 385-388
 - nutritional status and, 386-387
 - Environment, healing, 152
 - and sleep disorders, 229, 231
 - teaching/learning, 153
 - Epinephrine, for cardiac arrest, 73
 - Epworth Sleepiness Scale, 271
 - Esmolol hydrochloride, for atrial flutter, in children, 83-84
 - Ethics, leadership, 156
 - organizational, 156-157
 - Evidence-based practice, activities fostering expertise in, 132
 - in adult ICU, at Bay State Medical Center, 173-174

- capacity in, for organizational excellence,
127-132
for unit excellence, 136-137
committee functions for, 127-130
culture in, for organizational excellence,
132-133, 134-136
for unit excellence, 134-136
excellence in, **127-142**
indicators of success, 127-128
linkage within and across departments in, 129
medical intensive care unit sedation management,
evaluation of, 140
implementation of practice change in,
139-140
outcomes and results of, 140
synthesis of evidence in, 137-139
at University of Iowa Hospitals and Clinics,
127-142
vision in, for organizational excellence, 133-134
for unit excellence, 134, 137
- Evidence-based research, in adult ICU, at Bay State
Medical Center, 174
- Evidence-based thinking, in synergy model, 117-118
- Excellence, in evidence-based practice, **127-142**
organizational, 127-134
unit level, 134, 137
Methodist Hospital CCU as beacon of, **149-154**
organizational, in evidence-based practice,
127-134
vision in, 133-134
strategies for in adult ICU, **169-175**
- Exercise program, for sleep disorders, 232
- Experience of broken heart, **319-327**
- Extubation, of patients with obstructive sleep apnea,
respiratory depression following, 275
- F**
- Family, changes in, as center of children's lives,
451-452
parenting behaviors, 452
sibling relationships, 452-453
substitute care givers, 452
- Family presence, during CPR, **23-32**. See also
Siblings, presence in pediatric ICU.
for beginning of grief process, 25
of child, 20
definition of, 23
emotional responses of family members
and, 26
- ethical question of patient vs. family wishes
in, 27
family facilitator need in, 27-28
health care providers and, experiences with, 27
opposition of, 26
history of, 24
marketing of, 29
outcomes as context for, 23-24
patient's experiences with, research about,
26-27
physician vs. nurse attitudes and, 27
recommendations for new program, 28-29
research about family experiences with, 25-26
spiritual care and, 28
studies and evidence about, 25
- Family support, in healing environment, 172
- Fentanyl, central apnea and, 275
respiratory effect of, 274
for sedation, 261
in ventilated pediatric patient, 208
- Fibrinolysis, for acute coronary syndrome, 55
in pathophysiology of sepsis, 420
- Fluid, homeostasis of, 361
imbalances of, 362
maintenance, calculations for, 363
- Fluid and electrolyte balance, **361-373**
- Fluid and electrolytes, movement of, 362
post-cardiac surgery, 412
- Fluid and electrolyte therapy, in diabetic
ketoacidosis, 345
- Fluid compartment(s), extracellular, 361
intracellular, 361-362
- Fluid volume deficit, 362-363
dehydration in, types of, 363
management of, 363, 367
- Fluid volume overload, 362
- G**
- Gastrointestinal system, alcohol effect on, 298
- Genitourinary system, alcohol effect on, 298
- Glucose, post-resuscitation, in children, 18
- Glycoprotein IIb/IIIa, for acute coronary
syndrome, 55
for acute stroke, 55-57

H

- Haloperidol, in alcohol withdrawal syndrome, 302
- Handheld devices. See also *Personal digital assistant (PDA)*.
in critical care, 45–50
issues with, integration into practice, 46
patient safety, 46
scenarios for potential use, 45
- Harris scale, sedation assessment in, 290
- Healing environment, excellence and, 172
in medical ICU, 157
unit, 152
- Helium-oxygen mixture (heliox), for status asthmaticus, 470–471
- Hemodynamics, in children vs. in adults, 77–78
- Heparin, safe use of, 65
unfractionated, for acute coronary syndrome, 55
- Hepatic dysfunction. See *Liver dysfunction*.
- Heroin, for sedation, 260
- High-frequency oscillatory ventilation (HFOV), for acute lung injury, 313
for acute respiratory distress syndrome, 313
- Hormonal therapy, sleep disturbance and, 228
- Human factors, and safety, knowledge-based, 282–283
patient-related, 283–284
- Hydromorphone, for sedation, 260
- Hypercalcemia, overview and case example of, 365, 372
- Hyperglycemia, in diabetic ketoacidosis, 343–344
- Hyperkalemia, overview and case example of, 365, 370–371
- Hypermagnesemia, overview of, 366
- Hyponatremia, overview and case example of, 364, 368–369
- Hyperphosphatemia, overview of, 366
- Hyperventilation therapy, post-resuscitation, in children, 18
- Hypnotics, for sleep, pharmacology of, 273
for sleep disorders, 230
- Hypocalcemia, overview and case example of, 365, 371–372

- Hypokalemia, overview and case example of, 364, 369–370
- Hypomagnesemia, overview of, 365
- Hyponatremia, in diabetic ketoacidosis, 343
overview and case example of, 364, 367–368
- Hypophosphatemia, overview of, 366
- Hypotension, with hypothermia, 101
- Hypothalamus, in thermal regulation, 97
- Hypothermia, adverse consequences of, 101
effect on drugs used in cardiac arrest, 101
neuroprotection of, in cardiac resuscitation, 98

I

- Implantable cardioverter defibrillator (ICD),
biventricular, 9
description of, 9
- Implantable cardioverter defibrillator (ICD) storm,
assessment following, 13
care following, device programming, 13
immediate, 12–13
medical, 13
patient education, 13–14
psychological, 13–14
- cases, cardiac arrest and coronary artery disease, 11
coronary artery disease and atrial fibrillation, 12
coronary artery disease and cardiomyopathy, 11–12
coronary artery disease with dual-chamber ICD, 11
dilated cardiomyopathy with 20% left ventricular ejection, 10–11
- causes of, 10
comparison of patients with low and high numbers of storm shocks, 12
device programming and, 13
factors associated with, 10
incidence of, 9
issues for patients and families, 9–16
pain in, 12
patient counseling and, 14
patients at risk for, 10
- Indirect calorimetry, in nutritional assessment, 387–388
- Insomnia, 226
- Insulin, for diabetic ketoacidosis, 345–346
post-resuscitation, in children, 18
safety precautions with, 65–66

Interdisciplinary collaboration, 143–148

- barriers to, communication breakdown,
144–145
 - role ambiguity, 145–146
 - value variations, 145
- benefits of, 144
- definition of, 143–144
- drivers of, 144
- solutions for, achievement of foundation
for, 146
 - communication and coordination, 147
 - education, basic and continuing, 146
 - standards to support collaboration, 146

**International Guidelines 2000 Conference, on CPR
and emergency cardiac care, 51–58****International Guidelines 2000 Confer-
ence recommendations**

- for acute coronary syndrome, assessment and
management of, 55–56
- for acute stroke, 55–57
 - fibrinolytic therapy and, 56–57
 - mnemonic of 7 Ds in, 57
 - protocol development for, 57
- for advanced cardiac life support pharmacology,
53–55
 - amiodarone, 53–55
 - antiarrhythmics, 54–55
 - anticoagulation, 54
 - beta-blockers, 54
 - calcium channel blockers, 54
 - magnesium, 54
- airway management for health care providers,
52–53
- basic life support, 51–52, 63
- on CPR and emergency cardiac care, evidence-
based practice and, 51–52
- defibrillation, 52, 63
- electrical therapy, 52

**Internship program, at Bay State Medical Center,
172–173**

- for excellence in adult ICU, 172–173

Intra-atrial re-entry tachycardia (IART),

- postoperative, in children with congenital heart
disease, 80, 84–86

**Intracranial pressure (ICP) monitoring, post-
resuscitation, in children, 18**

J

- Junctional ectopic tachycardia, postoperative, in
children, 80, 86–88

K

- Ketamine, for status asthmaticus, 476
- Kidneys. *See also Renal dysfunction.*
 - function of, 248

L

- Learning, facilitator of, in synergy model, 118
- Liver, alcohol effect on, 298
- Liver dysfunction, pharmacokinetics of sedatives and
analgesics in, bioavailability, 245–246
 - clearance, 247–248
 - distribution, 246–247
 - metabolism, 247
 - protein binding of, 247–248
- Liver function, assessment of, 248
- Lorazepam, for sedation, 260
 - comparison with midazolam, 293–294
- Low cardiac output syndrome (LCOS), 375–383.
See also Cardiac output.
 - clinical signs and symptoms of, 377–379
 - diagnosis of, 379–380
 - etiology of, 377
 - management of, goals in, 380–381
 - pharmacologic, 381–382
 - postoperative, management of, 409–410

M

- Magnesium sulfate, for status asthmaticus, 471, 473
- Magnet designation, Beacon award, and primary
nursing, 163–167
- Magnet hospital designation, for nursing excellence,
Georgetown University Hospital, 160
University of California at Davis, 163
- Management team, unit, in evidence-based
practice, 136
- Maternal patients, transportation of, 208
- Mechanically ventilated patients, sleep in, 251–255.
*See also Sleep, in mechanically
ventilated patients.*
 - weaning from ventilator, 170–171
- Mechanical ventilation, for status asthmaticus,
474–476
 - indications for, 474–475
- Medication errors, action phases of, 281
 - in elderly patients, 284
 - in pediatric patient, 283–284

Medication safety. See also *Clarian Safe Passage Program; Safety*:

- with antipsychotic agents, 68–69
- crash carts, 67
- crash carts, pediatric, 67
- dosing errors and, 65
- in emergency department, **65–69**
- with heparin, 65
- with high-alert medications, 65–66
- with insulin, 65–66
- with nesiritide, 67–68
- on pediatric ICU, 437–438
- Rule of 6 and, calculation of concentrations of pediatric solutions, 66–67
- with thrombolytic and fibrinolytic agents, 66

Melioidosis, in tsunami victims, 488–491

Mentoring, technology and, 110–111

Mentoring staff members, **121–126**

Methodist Hospital coronary care unit, awards and acknowledgments received by, 153
as beacon of excellence, **149–154**
center for professional excellence in, 151
evidence-based practice in, 152–153
nursing clinical career progression model in, 150–151
relationship-centered care in, 152
shared governance model in, 149–150
teaching-learning environment in, 153
unit culture and mission in, 151–152

Mexylxanthines, for status asthmaticus, 472–473

Midazolam, cross-tolerance to, 212–213
for sedation, 260
comparison with lorazepam, 293–294
in neonates, 208–209
tolerance to, 212

Midazolam withdrawal, chart review of, in pediatric patients, 216

Milrinone, for low cardiac output syndrome, 381–382

Monitoring, of patients, failure to, 281

Morphine, for sedation, 260
for systemic analgesia, pharmacology of, 274
in ventilated neonate, 209
in ventilated pediatric patient, 208

Motor Activity Assessment Scale, 290–291

Myopathy, critical illness, 288, 444

N

Naltrexone, in alcohol withdrawal syndrome, 302

Near-death experience, in children, post-resuscitation, 19–20

Neonates, sedation of, in transportation, 208–209

Nesiritide, contraindications to, 67
dosing of, 68
incompatibility with injectable drugs, 67
medication safety with, contraindications to, 67

Networking, acute care nurse practitioner role, 170–180
resources for, 180–181

Neurologic examination, timing of, with bispectral technology, 263–264
hemodynamic variables and, 262
sedative half-life and, 262
subjective assessment and, 262

Neuromuscular blocking agents (NMBAs), adverse responses to, **441–450**
medications and conditions interacting with, 445
monitoring of, 445–446
muscle weakness acquired from, 444–445

Nitric oxide, inhaled, for low cardiac output syndrome, 382

Norepinephrine, for cardiac arrest, 73

Northwest MedStar, community and professional service of, 188–189
continuing education and, 190
description of, 190
nationally prominent staff members of, 189–190
response in rural areas, 189
success of, revenues in, 187–188
safety and, 188
transport of critically ill patient, **183–190**
accreditation of, 184
criteria for RN medical crew, 186
equipment, 186–187
ground support for, 187
history and evolution of, 183–185
indicators of success, 187
medical team, 184, 186
mission statement of, 184

Nursing excellence. See also *Excellence*.
magnet hospital designation for, Georgetown University Hospital, 160
University of California at Davis, 163–164

Nutritional assessment, definition of, 385–386
and enteral support, **385–393**
standard for, 388–389
techniques in, 386–388

Nutritional status, deterioration of, risks for, 386-387

Nutritional support. See also *Enteral support*.

formulas for, composition for, 389-390

indications for, 388-389

modes of, enteral, 391-392

total parenteral, 392

O

Obstructive sleep apnea (OSA). See also *Sleep apnea*.

anesthetic, sedative, and analgesic agents effects on, 274-276

in children, fentanyl and, 275

pharmacology and, 271-274

sedation in, 269-277

upper airway compliance in, 271

alcohol effect on, 271

benzodiazepine effect on, 271

Opiates, for sedation, 260

Opiate withdrawal syndrome, 212-213

Opioid-benzodiazepine combination, in sedation of pediatric patient, 208

Opioids, gastrointestinal motility and, 446-447

sleep and, pharmacology of, 273-274

Opioid withdrawal, 212

treatment of, 221

Organ dysfunction, in sepsis, 418-419

Organizational excellence, in evidence-based practice, 127-134

Orientation, competency-based, Georgetown

University Hospital, 158

for excellence in adult ICU, 172

synergy model of, in Clarian Health Partners, 116-117

nurse side, 116-117

patient side, 116

University of California at Davis, surgical ICU, 164-165

Outcomes, acute care nurse practitioner and, 180

of evidence-based practice, in medical intensive care unit sedation management, 140

family presence during CPR and, 23-24

patient, 158-159, 165-166

Oversedation. See also *Sedation*.

costs of, 289

with lorazepam, 294

neuromuscular impairment and, 288

in sedation-assessment conundrum, 259

Oxygen, for status asthmaticus, 470

Oxyhemoglobin dissociation curve, temperature effect on, 97-98

P

Pain, management of, in transportation setting, 206-207

sleep disruption and, 241-242

Palliative care, adult ICU team and, 171

Patient-controlled analgesia (PCA), respiratory depression with, 275-276

safety issues with, 280

Patient Outcomes, medical ICU, Georgetown

University Hospital, 158-159

surgical ICU, University of California at Davis, 165-166

Patient safety. See also *Clarian Safe Passage Program*.

mentoring staff members in, 121-126

synergy model and, 117

teamwork and conflict management and, 117

Pediatric advanced life support (PALS) guidelines, 59-64

for airway management, 61-62

for automatic external defibrillators, 62-63

for children with special needs, 61

endotracheal tube alternatives, 61

history of, 59

international advanced life support, 63

laryngeal mask airway, 61-62

"phone first" vs. "phone fast," 60-61

for post-arrest stabilization, 63

rhythm disturbance algorithms, 62

two-thumb compression technique in, 61

for vascular access, 62

visual changes in PALS manual, 60

Pediatric ICU, analgesics on, 242

BIS monitoring on, of sedation, 242

of sleep states, 242-243

safety in. See *Safety, in pediatric ICU*.

sedatives on, 242

sleep in, analgesic effect on, 242

BIS monitoring of, 242-243

nonpharmacologic methods for improving, 241

sedative effect on, 242

studies of, 240-241

sleep vs. sedation, 241-242

Peer review, in synergy model, 117

Pentobarbital, for sedation, 260

- Personal digital assistant (PDA), history and basics of, 46-47
integration into practice, adoption of, 49
arterial blood gas measurements, 45, 48
dosage calculation, 45, 48
drug check, 48
"S Curve of Technology Adopters" and, 49
operating systems for, 47
resources for practice, electronic texts for
downloading, 48
online search for health-related software, 47-48
safety at point of care, 47
selection of, considerations in, 49
vs. laptops or personal computers, 47
- Pharmacokinetics, of sedatives and analgesics, in critically ill patient, 212
effects of liver and renal dysfunction on, **245-250**
in liver dysfunction, 245-248
in renal dysfunction, 248-249
- Phenobarbital, for sedation, 260
- Pneumonia, risk in hypothermia, 101
- Point of care testing (POCT), in collaboration, 170
- Poisonings, activated charcoal for
age and, 397
alkalization of urine, for urinary excretion of, 403
antidotes in, 399-400
assessment and management of, **395-404**
assessment of, 397-399
ABCDEs in, 397-398
history in, 399
laboratory testing in, 399-400
physical examination, 398-399
toxidromes in, 398-399
characteristics of, 396
enhanced elimination, with multiple-dose activated charcoal, 402-403
gastric emptying for, gastric lavage in, 401
syrup of ipecac in, 401
gastrointestinal decontamination for, 400-402
recognition of, 395-396
substances involved in, 396-397
- Polyneuropathy, critical illness, 288
- Positive pressure ventilation, in patient transport, 205-206
- Potassium imbalances, overview and case examples, 364-365, 369-371
- Practice, strategies for acute care nurse, **169-175**
synergy model *versus* differentiated practice, 109-110
- Primary nursing, surgical ICU, University of California at Davis, Total Patient Care Model in, 166-167
- Procainamide, for atrioventricular re-entry tachycardia, in children, 83
- Professional development, in synergy model, 117-118
teamwork, impact on patient safety, 117
- Propofol, in pediatric ICU patients, 219
for sedation, 260
- Propofol withdrawal syndrome, 217-219
prevention of, 221
- Psychotherapy, for sleep disorders, 232-233
- Public policy, nurses' emerging role in, **191-199**
versus attitude of indifference, 191
awakening to, 191-192
current issues for, end-of-life care, 197-198
tobacco control, 196-197
educational shortcomings and, 192
influence on, collective, 193-196
individual, 192-193
legislative activities of organizations in, 194-195
revolution in the making, 198
stages of political development and, 192
- Pulseless rhythms, in children, 81, 93-94
-
- Q**
- Quality of care, on pediatric ICU, measurement and analysis of, 438-439
mortality prediction as indicator of, 434
safety in PICU and, 431
- Quality of life, after implantable cardioverter defibrillator (ICD) storm, 14
-
- R**
- Radiation therapy, sleep disturbance and, 228
- Ramsay Sedation Scale, 290
- Rapid sequence intubation (RSI), sedation in, 206, 209
- Recognition, of cues for endotracheal suctioning, **329-340**
of staff members, at Bay State Medical Center, 173
- Recruitment and retention, Georgetown University Hospital, 159-160
University of California at Davis, surgical ICU, 164

- Relationship-centered care, Methodist Hospital, 152
- Relaxation techniques, for sleep disorders, 232
- Remifentanyl, for sedation, 261
- Renal dysfunction, kidney function and, 248
- pharmacokinetics in, distribution, 248
 - drug clearance, 248
 - estimates of, 249
 - elimination, 248
 - metabolism, 248
- Renal function, post-resuscitation, in children, 18
- Respiratory complications, with oversedation, 288
- Respiratory depression, from IV PCA with and without basal infusion, 275-276
- Respiratory failure, in children, 78
- clinical signs and symptoms of, 78
- Resuscitation, pediatric, care following, 17-22
- simulation in teaching of, 1-8
- Resuscitation events. See also *Cardiopulmonary resuscitation (CPR)*.
- documentation of, 39-43
 - analysis of in-hospital adult cases, 42
 - future research in, 42-43
 - literature review of, 41
 - in pediatric care, 41
 - practice recommendations, 42
 - resuscitation teams and, 41
 - role of documentation nurse, 40
 - technologic devices in, 40-41
 - Ulstein guidelines for, 39-40, 42
 - National Registry for CPR Resuscitation and, 41
- Richmond Agitation-Sedation Scale (RASS), 291, 293
- Riker Sedation-Agitation Scale, 290-291
- Rule of 6, in calculation concentration in pediatric solutions, 66

S

Safety. See also *Clarian Safe Passage Program: Medication Safety*.

- Eindhoven classification system and, 279-283
 - human factors and, 281-284
 - organizational factors and, 280-282
 - technical factors and, 279-280
- of medical devices, failures of, in human interaction with, 279-280
- medication errors and, 281
- in patient transport, 188, 209

- PDA use and, 47
- prioritization of interventions and, 284
- proactive approaches to, 284
- reactive assessment of errors and, 284
- in sedation, classification systems in consideration and investigation of, 284
- sedation and, 279-285
- technical risks to, 279-280

- Safety in pediatric ICU, catheter-related bloodstream infections and, 435-436
- communication for, 433-434
 - endotracheal extubations and, unplanned, 436
 - and health care quality, 432
 - measurement and analysis of, 438-439
 - medication safety and, 437-438
 - mortality prediction as quality indicator and, 434
 - patient identification and, 435
 - quality outcomes and, 431-440
 - restraints and, 436-437
 - severity of illness adjusted length of stay for, 434-435
 - standardizing processes for, 432
 - transparency and, 438
 - working conditions for health care providers and, 431-432

Sedation. See also *Oversedation*.

- adaptation to the intensive care environment (ATICE) scale, 291, 293
- administration method for, 293-294
- adverse responses to, 441-450
 - cost associated with, 447-448
 - gastrointestinal, 446-447
 - tolerance, dependence, and withdrawal, 441-443
- analgesia vs., 241
- assessment of, during patient transport, 207
- case example of, 287
- complications of, and critical illness, 287-296
 - oversedation, 287-288
 - preventing, 289-292
- daily interruption of, 294
- disuse muscle atrophy and, 288-289
- guidelines for adult ICU, 171
- intravenous bolus vs. continuous infusion of, 294
- management of, on medical ICU, 137-140
- objective measures of, actigraphy, 292-293
- bispectral monitoring, 292
- in obstructive sleep apnea, 269-277. See also *Sleep*.
- patient safety and, 279-285
- in patient transportation, prehospital and interfacility, 205-207
- post-cardiac surgery, 413-414

- selection of agent for, 293
 - sleep and. See also *Sleep*.
 - in pediatric ICU, **239–244**
 - subjective measurement scales for, 289–292
 - tolerance and withdrawal with, **211–223**
- Sedation–assessment conundrum, **257–267**. See also *Sedation*.
- case presentation, 257–258
 - definition of, 258
 - neuroscience examination in. See also *Neurologic examination*.
 - bispectral monitor in, 262–264
 - change in level of consciousness in, 262
 - response to central pain in, 261–262
 - reticular activating system in, 261–262
 - sedation interruption in, 263
 - timing of, 262
 - requirements of neurologic examination vs. ventilatory and hemodynamic requirements, 267
 - sedation in, challenges of, 259–261
 - goals of, 258–259
 - oversedation, 259
 - undersedation and, 259–261
- Sedation withdrawal, strategies for, in concomitant use of opioids, 221
- with DEX, 221
 - switch to long-acting oral sedatives, 220
 - tapering and weaning, 220
- Sedatives, pharmacokinetics of, in critically ill patient, 212
- in hepatic dysfunction, 245–248
 - in renal dysfunction, 248–249
- Sedative withdrawal syndromes, comparison with alcohol withdrawal, 211–212
- Sepsis, **417–429**
- antibiotic therapy for, 425–426
 - clinical manifestations of, 421–422
 - definitions, 417–419
 - etiology of, 419
 - hemodynamic response in, 420–421, 423
 - with hypothermia, 101
 - infection in, 417–419
 - management of, alternative therapies, 427–428
 - antibiotics in, 425–426
 - coagulation abnormalities, 426–427
 - collaborative, 423–427
 - decrease in energy expenditure, 427
 - initial resuscitation, 424
 - metabolic, 416
 - nutritional, 426
 - ongoing, 424
 - pharmacologic, 425–426
 - renal, 426
 - respiratory, 426
 - monitoring and laboratory data in, 422–423
 - organ dysfunction in, 418–419
 - outcomes in, 428
 - pathophysiology of, 419–420
 - coagulation in, 419–420
 - endothelium in, 420
 - fibrinolysis in, 420
 - inflammatory response in, 419
 - shock in, 421–422
- Shared governance, components of, 149–150
- Shock, clinical signs and symptoms of, 78
- definitions of, 421
 - septic, phases and symptoms of, 421–422
- Siblings, death and, 459–460
- perspective of critical illness, emotions and behaviors in, 453–454
 - influence of maturation and experiences in, 453
 - presence in pediatric ICU, **451–461**. See also *Family presence, during CPR*.
 - alternatives to, 458
 - benefit of, to family adaptation, 454
 - care givers' resistance to, 454–455
 - concerns about death and, addressing, 459–460
 - creation of child-friendly atmosphere for, 460
 - guidance of visit, 457–459
 - health screening for, 457–458
 - parent's guide to helping children visit, 456–457
 - policy for, 455–459
 - preparation of parents for, 457
- Simulation, of competent, proficient, and expert learners, 6–7
- in health care education, 1–2
 - Dreyfus model of skill acquisition and, 5
 - from novice to advanced beginner, 5–6
 - high-fidelity, 2–3
 - evidence-based research for, 7
 - need for cost/benefit ratio study of, 7
 - program development for, system, equipment, educational factors in, 2
 - terms for devices and systems in, 2
 - at Veterans Administration San Diego Health Care System and University of California at San Diego, in advanced cardiac life support, 5
 - of code blue, critical care team, 5
 - in medical surgical course for nurses, 4–5
 - simulation laboratory, 3–5

- Sleep, apneic, types of, 269–270
 basic mechanisms of, 269–270
 in children, normal, 240
 in pediatric ICU, 240–243. See also
 Pediatric ICU.
 definition of, 239
 disruption of, effects of, 240
 importance of, 226
 in mechanically ventilated patients, **251–255**
 impaired, causes of, 253–254
 objective evaluations of, 253
 recommendations for care of, 254
 research on, problems in, 252
 subjective evaluations of, 252–253
 need for, 251–252
 normal, 251–252
 in children, 240
 in pediatric ICU, sedation and, **239–244**
 processes of, 225
 REM, 239
 REM and non-REM, 225, 240
 slow wave, 239, 251
 stages of, 270
 vs. sedation, 241–242
- Sleep apnea. See also *Obstructive sleep apnea (OSA)*.
 assessment of, 270–271
 polysomnography, overnight, 270
 subjective tools for, 270–271
 types of, 269–270
- Sleep deprivation, in cancer patients, psychosocial
 impact of, **225–237**
 consequences of, 239
- Sleep disorders, in patients with cancer, **225–237**
 clinical sequelae of, 230
 cytokine production and, 229
 environment and, 229
 etiologic factors in, 227–230
 non-pharmacologic interventions for, 231–233
 nursing implications of, identification of
 cause, 233
 identification of patients, 233
 psychosocial support, 234
 scheduling of activities, 234
 sleep hygiene strategies, 233–234
 pain and, 227–228
 pharmacologic interventions for, 230–231
 prevalence of, 226
 psychologic factors and, 229–230
 treatment-related causes of, 228–229
 tumor effects and, 228
 types of, 226
- Sleep schedules, for sleep disorders, 231
- Sodium bicarbonate, post-resuscitation, in
 children, 18
- Sodium imbalances, overview and case examples,
 364, 367–369
- Sodium nitroprusside, for low cardiac output
 syndrome, 382
- Staff support, in healing environment, 172
- Standards of care, safety and, 281
- Status asthmaticus, assessment of, clinical diagnostics
 in, 468–469
 clinical scoring in, 467
 patient history in, 467–468
 physical examination in, 469
 epidemiology of, 463
 future therapies for, 476
 management of, clinical, 470, 473–476
 in pediatric ICU, **463–479**
 pharmacologic, 469–473, 476
 pathophysiology of, 463–464
 cellular manifestations of, 464–465
 clinical manifestations of, 465–467
- Sudden cardiac death, description of, 33
 implantable cardioverter defibrillator prevention
 of, **33–38**
 for community practice, 37
 implications of, for primary and secondary
 prevention, 37
 for research and policy, 37–38
 indications for, AHA Class I and Class II,
 36–37
 primary, 33
 in coronary artery disease, 35
 in heart failure, 35–36
 implications of, 37
 secondary, 33
 clinical trials in, 34–35
 populations at risk for, 34
 prevention of, implantable device therapy in,
 33–38
 as public health problem, 33
- Support, of family and staff, in healing
 environment, 172
- Supraventricular tachycardia, in children, atrial
 flutter, 80, 83–84
 intra-atrial re-entrant, 80, 83–84
 junctional ectopic, postoperative, 80, 86–88
 in neonates and infants, atrial flutter, 80, 83–84
 atrioventricular re-entrant, 79–80, 82
- Synergy, for leadership development, **113–119**
 as mentoring model, **109–112**

- Synergy model, as basis for mentoring, 110
 Clarian Professional Practice Model and, 109
 in clinical nursing education, 115-118
 versus differentiated practice, 109-110
 for leadership development, 113-115
 learners in, 115
 management development in, 118
 nurse characteristics in, 114, 115
 nursing administrative staff in, 115
 orientation in, 116-117
 patient needs and characteristics in, 113
 professional development in, 117-118
 technology and mentoring in, 110-111
 environmental side of, 113
 management development in, 118
 patient characteristics in, 122

Systemic inflammatory response syndrome (SIRS),
 criteria for, 417

T

- Tachyarrhythmia(s), in children, 78
 supraventricular tachycardia, 79-80, 82-88
 ventricular tachycardia, in congenital long QT
 syndrome, 81, 89-91

Technology, mentoring and, 110-111

Temperature management, post-resuscitation, in
 children, 18

- Thermoregulation, in cardiac resuscitation, **97-102**
 current studies, 98-99
 hypothermia and neuroprotection, 98
 temperature measuring devices and, 99-100
 physiologic mechanisms of, for heat loss, 97
 for metabolic heat production, 97
 temperature effect on oxyhemoglobin dissociation
 curve, 97-98

Thick filament myopathy (TFM), 444

Thrombolytic agents, dosage and administration
 of, 66

Tobacco control, public policy and, nurses' emerging
 role in, 196-197

- Tolerance, to analgesics, 441-443
 defined, 211
 definition of, 441
 to DEX, in animal studies, 219-220
 pharmacokinetic and pharmacodynamic, 217
 to propofol, in adult ICU patients, 217-219
 to sedatives, 211, 441-443
 types of, 211

Torsades de pointes, in children, 81, 89-91

Toxidromes, 398-399

- Transportation, air medical transport, 207
 behavioral issues concurrent with patient's
 medical or trauma status, 206
 complications in, 209
 of critically ill patient. *See Northwest MedStar,*
 transport of critically ill patient.
 ground, 207
 of maternal patients, 208
 mode considerations, 207
 of neonates, 208-209
 operational safety considerations in, 209
 of pediatric patients, 208
 prehospital and interfacility, airway management
 in, 205-206
 mode considerations in, 207
 pain management in, 206-207
 sedation and, 205-207

Traumatic brain injury, airway management in, 206

- Tsunami disaster, children in, decision not to
 treat, 487
 mortality before and after, 487, 493
 value of in disasters, 492
 chronology, 481-482
 need for international pediatric intensive care
 disaster team, 482-493
 response from Belgium
 assistance from German medical intervention,
 486-487
 Banda Aceh hospital conditions, 484-486
 case examples, 487-489
 collaboration with Australian team, 487
 collaboration with other medical teams,
 491-492
 cultural differences of Acehnese doctors, 491
 French replacement of Belgian medical
 teams, 492
 incorporation of Spanish team in, 491
 Jakarta staff and, 491
 medical teams 2 and 3, 489-490
 preparation of medical team to assist, 483
 Sigli refugee camp, condition of children, 484
 response to, **481-494**

U

- Unit, and excellence in evidence-based practice,
 134-137
 as system in synergy model, 118

University of California at Davis, magnet hospital
 designation of, 163-165

V

-
- Vancouver Interaction and Calmness Scale, 290–292
- Vasopressin, for cardiac arrest, 73
- Vasopressors, for cardiac arrest, 71–75
- Ventilatory support, for status asthmaticus, 474–476
- Ventricular fibrillation, in children, 81, 93–94
- Ventricular tachycardia, in congenital long QT syndrome, 81, 88–91
incessant, in very young children, 81, 88–89
- Vision, in evidence-based practice, 133–134
for organizational excellence, 133–134
- Vital signs, parameters in children, 78

W

-
- Weaning and extubation from mechanical ventilation, adult ICU protocol, 170–171

- Withdrawal, alcohol and drug, definition of, 441
risk for, 442
symptoms of, 443
therapy for, 443–444

- Withdrawal of life support, analgesia or sedation during, 353
decision-making in, 352–353

- Withdrawal syndromes, alcohol. See *Alcohol withdrawal syndrome*.
benzodiazepine. See *Benzodiazepine (BZD) withdrawal syndrome*.
sedative. See *Sedative withdrawal syndromes*.

Z

-
- Zaleplon, for sleep, 273
- Zolpidem, for sleep, 273

